Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-353-2 | CAS number: 57-88-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Toxicokinetic assessment based on all available information from the open literature as well as on the physico-chemical properties of cholesterol.
Key value for chemical safety assessment
- Absorption rate - oral (%):
- 60
- Absorption rate - dermal (%):
- 60
- Absorption rate - inhalation (%):
- 100
Additional information
Toxicokinetic assessment
oral
Absorption and Distribution:
Dietary absorption occurs from the gut via lymph, mainly from the proximal small intestine. Cholesterol is incorporated, with use of bile salts, into chylomicrons (mixed micelles). Once the chylomicrons are absorbed into the lymph, they are transported to the liver, where cholesterol is incorporated (both absorbed and in liver synthesized) into very low-density lipids (VLDL) intermediate-density lipids (IDL) and low-density lipids (LDL). LDL enters the circulatory system where it will be metabolized, as well as excreted in bile, feces, urine, milk or skin.Intake of cholesterol via food influences the total body cholesterol, as exchange between the cholesterol pools will occur. The total cholesterol pool consists intake of cholesterol (about 500 g/day), endogenous synthesis (intestine about 400 mg/day, liver about 1000 mg/day, and other organs), and back resorption from the intestine (about 50% of total excreted cholesterol). The total amount synthesized in the body is about 1.20 grams per day. In addition, about 0.30 grams is absorbed, and 0.5 grams reabsorbed. Excretion is about 1 gram per day. However uptake in the intestine depends on the amount in food and synthesis in the liver.
Cholesterol biosynthesis is regulated by negative feedback where the presence of cholesterol inhibits its own synthesis. The cholesterol turnover in plasma lipoproteins is approximately 1.11 g/day, as measured with stable and radioactive isotopes. In studies concerning cholesterol absorption from the diet (16 to 77 days), it was shown that there is a wide range of basal plasma cholesterol levels (115-717 mg/100 mL). Mean cholesterol intake in Germany (1969 -1970) was 584 mg, with individual significant deviations. Effects (disturbances) on the cholesterol balance will be observed with delay on plasma cholesterol concentration. Interruption of body synthesis provides the major controlling mechanism (70%)of the absorbed dietary cholesterol.The magnitude of the compensatory mechanisms was similar in normal and in hypercholesterolemic persons.
This information shows that there is a balanced system in mammals for uptake and excretion of cholesterol resulting in equilibrium. From the available literature on toxicokinetics of cholesterol, it can be concluded that oral absorption is about 60%, as determined by radio-labeled cholesterol studies as plasma ratio oral/intravenous tracer (30 mg oral, 15 mg i.v.). After oral administration, highest plasma levels are observed on day 2 after administration.
metabolism
In a repeated dose toxicity study with mice fed diets supplemented with 1% choline for 4 weeks and then switched to control diet for another 4 weeks only a slightly raised hepatic cholesterol concentration was observed. There are two major metabolic pathways of cholesterol in mammals: metabolism to bile acids (humans:~600 mg cholesterol/day) in the liver, and metabolism to steroid hormones (humans:~40 mg cholesterol/day) in the adrenals, testes, ovaries and placenta. Besides, cholesterol is also metabolized into cholesterol esters, cholesterol sulfate, cholestanol and vitamin D3. In the gut, cholesterol is also metabolized by intestinal flora to several compounds, predominantly coprostanol and coprostanone.
Recommended cholesterol intake is 300 mg/day. Cholesterol absorption from the GI-tract is a key component of whole body cholesterol metabolism (with 2-fold larger enterohepatic recirculation of endogenous cholesterol). Cholesterol is present in 0.2% of the total human body, with most cholesterol membrane-associated. About 5% of this cholesterol is contained in the plasma. The function in membranes is related to the fluidity of the membrane, whereas cholesterol also plays a role as metabolic precursor to other steroids, such as adrenal corticosteroids, sex hormones, bile salts and provitamin D2.
Excretion
Cholesterol and its derivatives are excreted in the intestine as neutral steroids and bile acids (about 500 mg/day). Cholesterol is eliminated from the body via the feces, urine and skin surface (about 100 mg/day). Excretion of cholesterol via feces is in the form of bile salts, cellular and membrane cholesterol from cells from the intestine, unabsorbed dietary cholesterol and metabolic products of gut bacteria. Cholesterol and its derivatives excreted in the feces accounts for about 50% of the total cholesterol turnover in man. In urine, cholesterol (free and conjugated and as metabolites of steroid hormones) is a normal constituent. Cholesterol is also eliminated in the milk of lactating females.
Overall, there is a balanced system in mammals for uptake and excretion of cholesterol resulting in equilibrium.
inhalation
No data on inhalation absorption are available in the open literature. Consequently, the percentage inhalation absorption will be related to the physical-chemical properties of cholesterol.
In humans, particles with aerodynamic diameters below 100µm have the potential to be inhaled. Based on the information on particle size of cholesterol, particles <100µm which have the potential to be inhaled are present. For the particles that have the potential to be inhaled, they will be settled in the nasopharyngeal region (larger particles <100µm), thoracic region (particles <50µm) or alveolar region (particles <15µm). Part of the deposits in the nasopharyngeal region will be coughed or sneezed out of the body, or swallowed, while a part will dissolve into the mucus lining of the respiratory tract epithelium. For risk assessment purposes, the inhalation absorption of cholesterol is set at 100% as a worst case assumption.
dermal
Cholesterol is a component of skin surface lipids and sebum. Skin surface lipids contain 2-20% sterols (90-95% being cholesterol). Sebum from the forearms generally contains about 5% cholesterol (half in the free form, half esterified) (9). No data on dermal absorption are available in the open literature. Consequently, the percentage dermal absorption will be related to the physical-chemical properties of cholesterol.
According to the criteria given in the REACH Guidance (2), 10% dermal absorption will be considered in case MW>500 and log Pow <-1 or >4, otherwise 100% dermal absorption should be used. As the criteria for 10% dermal absorption are not met, 100% dermal absorption should be considered for risk assessment purposes. It is, however, generally accepted that dermal absorption is lower compared to oral absorption. The 100% dermal absorption derived from the physical/chemical properties of the substance should therefore be considered a non-realistic worst case assumption, and for risk assessment purposes a lower dermal absorption value of 60% is considered more appropriate.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.